BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 32495240)

  • 1. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.
    Walsh EA; Chabria R; Vranceanu AM; Park ER; Post K; Peppercorn J; Temel JS; Greer JA; Jacobs JM
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13723. PubMed ID: 36196499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
    Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
    Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
    Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
    Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
    Post KE; Ahmad Z; Jankauskaite G; Centracchio J; Oswald L; Horick N; Park ER; Temel JS; Greer JA; Jacobs J
    J Pain Symptom Manage; 2024 Jan; 67(1):88-97. PubMed ID: 37816436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Refinement of a Telehealth Intervention for Symptom Management, Distress, and Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
    Jacobs JM; Walsh EA; Rapoport CS; Antoni MH; Park ER; Post K; Comander A; Peppercorn J; Safren SA; Temel JS; Greer JA
    J Clin Psychol Med Settings; 2021 Sep; 28(3):603-618. PubMed ID: 33219901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
    Walsh EA; Post K; Massad K; Horick N; Antoni MH; Penedo FJ; Safren SA; Partridge AH; Peppercorn J; Park ER; Temel JS; Greer JA; Jacobs JM
    Breast Cancer Res Treat; 2024 Apr; 204(3):547-559. PubMed ID: 38231313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
    Clancy C; Lynch J; OConnor P; Dowling M
    Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.
    Green SMC; French DP; Graham CD; Hall LH; Rousseau N; Foy R; Clark J; Parbutt C; Raine E; Gardner B; Velikova G; Moore SJL; Buxton J; ; Smith SG
    BMC Health Serv Res; 2022 Aug; 22(1):1081. PubMed ID: 36002831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
    En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review and Meta-Analysis of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors.
    Bright EE; Finkelstein LB; Nealis MS; Genung SR; Wrigley J; Gu HCJ; Schmiege SJ; Arch JJ
    J Clin Oncol; 2023 Oct; 41(28):4548-4561. PubMed ID: 37531593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.